GT
NVO

Glenview Trust’s Novo Nordisk NVO Stock Holding History

Glenview Trust’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$251K Sell
6,822
-139
-2% -$6.59K ﹤0.01% 453
2025
Q4 		$354K Sell
6,961
-23,367
-77% -$1.19M 0.01% 410
2025
Q3 		$1.68M Buy
30,328
+9,011
+42% +$527K 0.03% 240
2025
Q2 		$1.47M Buy
21,317
+746
+4% +$50.7K 0.03% 238
2025
Q1 		$1.43M Buy
20,571
+5
+0% +$413 0.03% 234
2024
Q4 		$1.77M Buy
20,566
+7,369
+56% +$797K 0.03% 216
2024
Q3 		$1.57M Buy
13,197
+3,790
+40% +$505K 0.03% 230
2024
Q2 		$1.34M Buy
9,407
+129
+1% +$17.1K 0.03% 233
2024
Q1 		$1.19M Buy
9,278
+2,216
+31% +$264K 0.03% 242
2023
Q4 		$731K Buy
7,062
+714
+11% +$70.6K 0.02% 285
2023
Q3 		$577K Buy
6,348
+182
+3% +$16K 0.02% 295
2023
Q2 		$499K Buy
6,166
+348
+6% +$28.4K 0.01% 320
2023
Q1 		$463K Buy
5,818
+1,300
+29% +$92.2K 0.01% 327
2022
Q4 		$306K Hold
4,518
– – 0.01% 365
2022
Q3 		$225K Hold
4,518
– – 0.01% 384
2022
Q2 		$252K Buy
4,518
+128
+3% +$7.1K 0.01% 369
2022
Q1 		$244K Hold
4,390
– – 0.01% 388
2021
Q4 		$246K Hold
4,390
– – 0.01% 382
2021
Q3 		$211K Buy
+4,390
New +$212K 0.01% 389
2018
Q1 		– Sell
-14,626
Closed -$392K – 334
2017
Q4 		$392K Hold
14,626
– – 0.03% 260
2017
Q3 		$352K Hold
14,626
– – 0.03% 258
2017
Q2 		$314K Hold
14,626
– – 0.02% 265
2017
Q1 		$250K Buy
14,626
+1,100
+8% +$19.2K 0.02% 288
2016
Q4 		$243K Buy
+13,526
New +$245K 0.02% 280

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Glenview Trust's NVO Position: Q1 2026 in Review

Glenview Trust reduced its Novo Nordisk (NVO) stake by 2% in Q1 2026, selling an estimated $6.59K and leaving 6,822 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #453.

Glenview Trust first reported a position in NVO in Q4 2016 and has held it in 24 quarters since. The position peaked at $1.77M in Q4 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Glenview Trust held 6,822 shares of Novo Nordisk worth $251K as of Q1 2026.
  • Glenview Trust sold 139 Novo Nordisk shares in Q1 2026, an estimated $6.59K.
  • Novo Nordisk made up ﹤0.01% of Glenview Trust's portfolio in Q1 2026, its #453 holding.
  • Glenview Trust first reported a position in Novo Nordisk in Q4 2016 and has held it in 24 quarters since.
  • Glenview Trust's Novo Nordisk position peaked at $1.77M in Q4 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Glenview Trust's 13F filing for Q1 2026, filed 8 May 2026.